AxoGen (AXGN) versus Integer Holdings (ITGR) Financial Survey

AxoGen (NASDAQ: AXGN) and Integer Holdings (NASDAQ:ITGR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.

Earnings & Valuation

This table compares AxoGen and Integer Holdings’ gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	EBITDA	Earnings Per Share	Price/Earnings Ratio
AxoGen	$50.02 million	10.40	-$8.05 million	($0.42)	-37.26
Integer Holdings	$1.41 billion	1.01	$275.57 million	N/A	N/A

Integer Holdings has higher revenue and earnings than AxoGen.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for AxoGen and Integer Holdings, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	0	0	6	0	3.00
Integer Holdings	0	2	0	0	2.00

AxoGen currently has a consensus price target of $15.90, suggesting a potential upside of 1.60%. Integer Holdings has a consensus price target of $35.00, suggesting a potential downside of 22.05%. Given AxoGen’s stronger consensus rating and higher probable upside, research analysts clearly believe AxoGen is more favorable than Integer Holdings.

Institutional and Insider Ownership

64.6% of AxoGen shares are owned by institutional investors. 9.3% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares AxoGen and Integer Holdings’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AxoGen	-27.50%	-114.64%	-27.71%
Integer Holdings	N/A	N/A	N/A

Volatility & Risk

AxoGen has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Integer Holdings has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.

About AxoGen

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

About Integer Holdings

Greatbatch, Inc. is a developer and manufacturer of medical devices and components. The Company operates through two segments: Greatbatch Medical and QiG Group (QiG). Greatbatch Medical designs and manufactures products where the Company either owns the intellectual property or has unique manufacturing and assembly expertise. Greatbatch Medical’s products include medical devices and components for the cardiac, neuromodulation, orthopedics, portable medical, vascular and energy markets. QiG focuses on developing medical device systems for some of healthcare’s challenges and reflects the Company’s strategic evolution of its product offerings in order to raise the growth and profitability profile of the Company. QiG utilizes a diversified portfolio approach with three investment modes: new medical device systems commercialization, collaborative programs with OEM customers and strategic equity positions in emerging healthcare companies.